Phenotypes Associated with This Genotype

Genotype
MGI:2678248

• Allelic Composition: Prkn^tm1Roo/Prkn^tm1Roo
• Genetic Background: either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6)

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

decreased exploration in new environment ( J:85561 )

abnormal stationary movement ( J:85561 )

• reduced amphetamine-induced motor activity

growth/size/body

decreased body weight ( J:85561 )

• reduced body weight after weaning, both males and females

homeostasis/metabolism

decreased core body temperature ( J:85561 )

• reduced rectal temperature relative to wild-type

increased dopamine level ( J:85561 )

• increased in the limbic brain areas

• increased levels of the MAO-derived metabolite, DOPAC, relative to COMT-derived metabolite, 3-MT, indicating an impairment of dopamine release

muscle

muscle phenotype ( J:85561 )

N • no evidence of muscle degeneration

nervous system

nervous system phenotype ( J:85561 )

N • brain morphology, weight, and size were normal

abnormal synaptic transmission ( J:85561 )

• inhibition of dopamine neurotransmission

• inhibition of glutamate neurotransmission

• normal levels of 5-HT and 5-HIAA in the striatum, limbic system, diencephalon, and brainstem

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Parkinson's disease 2		DOID:0060368	OMIM:600116	J:85561